University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jennie Taylor, MD, MPH

Jennie Taylor, MD, MPH

Assistant Professor of Clinical Neurology, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Education

Randolph-Macon Woman's College, B.S., 06/01, Biology
University of Kentucky College of Medicine, M.D., 06/07
University of Virginia, Intern, 06/08, Internal Medicine
University of Virginia, Resident, 06/10, Neurology
University of Virginia Chief Resident, 06/11, Neurology
Partners Neuro-Oncology Fellowship (Massachusetts General Hospital/Dana Farber Cancer Institute/Brigham and Women's Hospital), Clinical Fellow, 06/12, Neuro-Oncology
Edwin L. Steele Lab of Tumor BiologyMassachusetts General Hospital, Research Fellow, 06/14, Neuro-Oncology
Harvard School of Public Health, MPH, 06/14, Public Health


Professional Experience

  • 2014-present
    Assistant Professor, Neurology and Neurosurgery, UCSF

Honors & Awards

  • 2007
    General Clinical Research Center Medical/Dental Mentorship Award, University of Kentucky College of Medicine
  • 2010
    Chief resident in Neurology, University of Virginia College of Medicine
  • 2012
    K12 training grant recipient, "Training Program in Nervous System Tumors", Massachusetts General Hospital

Selected Publications

  1. Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017 Jun; 133(6):1001-1016.
    View on PubMed
  2. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 Mar; 79(3):603-610.
    View on PubMed
  3. Chan AK, Birk HS, Winkler EA, Viner JA, Taylor JW, McDermott MW. Stability of Programmable Shunt Valve Settings with Simultaneous Use of the Optune Transducer Array: A Case Report. Cureus. 2016 Jul 07; 8(7):e675.
    View on PubMed
  4. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53; discussion 253.
    View on PubMed
  5. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  6. Taylor JW, Schiff D. Treatment considerations for MGMT-unmethylated glioblastoma. Curr Neurol Neurosci Rep. 2015 Jan; 15(1):507.
    View on PubMed
  7. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
    View on PubMed

Go to UCSF Profiles, powered by CTSI